These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38581432)

  • 1. What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult Individual Perspective?
    Bartsch SM; O'Shea KJ; Weatherwax C; Strych U; Velmurugan K; John DC; Bottazzi ME; Hussein M; Martinez MF; Chin KL; Ciciriello A; Heneghan J; Dibbs A; Scannell SA; Hotez PJ; Lee BY
    J Infect Dis; 2024 Aug; 230(2):382-393. PubMed ID: 38581432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.
    Sandmann FG; Davies NG; Vassall A; Edmunds WJ; Jit M;
    Lancet Infect Dis; 2021 Jul; 21(7):962-974. PubMed ID: 33743846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling the potential public health and economic impact of different COVID-19 booster dose vaccination strategies with an adapted vaccine in the United Kingdom.
    Harrison C; Butfield R; Yarnoff B; Yang J
    Expert Rev Vaccines; 2024; 23(1):730-739. PubMed ID: 39072472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study.
    He X; Zeng B; Wang Y; Pang Y; Zhang M; Hu T; Liang Y; Kang M; Tang S
    Front Immunol; 2023; 14():1257360. PubMed ID: 37915583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022.
    Danza P; Koo TH; Haddix M; Fisher R; Traub E; OYong K; Balter S
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(5):177-181. PubMed ID: 35113851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of SARS-CoV-2 vaccines on Covid-19 incidence and mortality in the United States.
    Fang F; Clemens JD; Zhang ZF; Brewer TF
    PLoS One; 2024; 19(4):e0301830. PubMed ID: 38656933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.
    Antonelli M; Penfold RS; Canas LDS; Sudre C; Rjoob K; Murray B; Molteni E; Kerfoot E; Cheetham N; Pujol JC; Polidori L; May A; Wolf J; Modat M; Spector T; Hammers A; Ourselin S; Steves C
    J Infect; 2023 Dec; 87(6):506-515. PubMed ID: 37777159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans.
    Laniece Delaunay C; Mazagatos C; Martínez-Baz I; Túri G; Goerlitz L; Domegan L; Meijer A; Rodrigues AP; Sève N; Ilic M; Latorre-Margalef N; Lazar M; Maurel M; Melo A; Andreu Ivorra B; Casado I; Horváth JK; Buda S; Bennett C; de Lange M; Guiomar R; Enouf V; Mlinaric I; Samuelsson Hagey T; Dinu S; Rumayor M; Castilla J; Oroszi B; Dürrwald R; O'Donnell J; Hooiveld M; Gomez V; Falchi A; Kurecic Filipovic S; Dillner L; Popescu R; Bacci S; Kaczmarek M; Kissling E;
    JAMA Netw Open; 2024 Jul; 7(7):e2419258. PubMed ID: 38949812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postacute symptoms 4 months after SARS-CoV-2 infection during the Omicron period: a nationwide Danish questionnaire study.
    Spiliopoulos L; Sørensen AIV; Bager P; Nielsen NM; Hansen JV; Koch A; Meder IK; Videbech P; Ethelberg S; Hviid A
    Am J Epidemiol; 2024 Aug; 193(8):1106-1114. PubMed ID: 37981717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization.
    Kohli M; Maschio M; Becker D; Weinstein MC
    Vaccine; 2021 Feb; 39(7):1157-1164. PubMed ID: 33483216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination.
    Bartsch SM; Wedlock PT; O'Shea KJ; Cox SN; Strych U; Nuzzo JB; Ferguson MC; Bottazzi ME; Siegmund SS; Hotez PJ; Lee BY
    J Infect Dis; 2021 Sep; 224(6):938-948. PubMed ID: 33954775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
    Abu-Raddad LJ; Chemaitelly H; Ayoub HH; AlMukdad S; Yassine HM; Al-Khatib HA; Smatti MK; Tang P; Hasan MR; Coyle P; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R
    N Engl J Med; 2022 May; 386(19):1804-1816. PubMed ID: 35263534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Follow-up SARS-CoV-2 serological study of a health care worker cohort following COVID-19 booster vaccination.
    Hönning A; Tomczyk S; Hermes J; Grossegesse M; Hofmann N; Michel J; Neumann M; Nitsche A; Hoppe B; Eckmanns T; Schmidt-Traub H; Zappel K
    BMC Infect Dis; 2024 Apr; 24(1):436. PubMed ID: 38658874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effectiveness of booster vaccination of inactivated COVID-19 vaccines against susceptibility, infectiousness, and transmission of omicron BA.2 variant: a retrospective cohort study in Shenzhen, China.
    Liao Y; Su J; Zhao J; Qin Z; Zhang Z; Gao W; Wan J; Liao Y; Zou X; He X
    Front Immunol; 2024; 15():1359380. PubMed ID: 38881892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection Conferred by COVID-19 Vaccination, Prior SARS-CoV-2 Infection, or Hybrid Immunity Against Omicron-Associated Severe Outcomes Among Community-Dwelling Adults.
    Lee N; Nguyen L; Austin PC; Brown KA; Grewal R; Buchan SA; Nasreen S; Gubbay J; Schwartz KL; Tadrous M; Wilson K; Wilson SE; Kwong JC
    Clin Infect Dis; 2024 May; 78(5):1372-1382. PubMed ID: 38001037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.
    León TM; Dorabawila V; Nelson L; Lutterloh E; Bauer UE; Backenson B; Bassett MT; Henry H; Bregman B; Midgley CM; Myers JF; Plumb ID; Reese HE; Zhao R; Briggs-Hagen M; Hoefer D; Watt JP; Silk BJ; Jain S; Rosenberg ES
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):125-131. PubMed ID: 35085222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States.
    Li R; Liu H; Fairley CK; Zou Z; Xie L; Li X; Shen M; Li Y; Zhang L
    Int J Infect Dis; 2022 Jun; 119():87-94. PubMed ID: 35338008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling the potential public health impact of different vaccination strategies with an adapted vaccine in South Africa.
    Al Akoury N; Spinardi J; Haridy H; Molefe-Osman N; Mphahlele N; Mendoza CF; Yang J; Aruffo E; Kyaw MH; Yarnoff B
    Expert Rev Vaccines; 2024; 23(1):750-760. PubMed ID: 39176448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.